47. Clinical benefit table: Orthovisc. Dichotomous outcome measures.
Study | Time | Treatment | Outcome | No. improved | No. of pts. | Risk (%) | Risk difference | NNT |
Brandt 2001 | 14‐26 wk | E: Orthovisc | WOMAC pain (number of patients improved) | 61 | 66 | 92 | 5 | 20 |
C: Saline | 60 | 69 | 87 | |||||
Brandt 2001 | 14‐26 wk | E: Orthovisc | WOMAC pain greater than 5 unit improvement | 38 | 66 | 58 | 17 | 5.9 |
C: Saline | 28 | 69 | 41 | |||||
Tekeoglu 1998 | 1‐4 wk | E: Orthovisc | Patient global (number of patients good/very good) | 10 | 20 | 50 | ‐10 | 10 |
C: Betamethasone | 12 | 20 | 60 | |||||
Tekeoglu 1998 | 5‐13 wk | E: Orthovisc | Patient global (number of patients good/very good) | 15 | 20 | 75 | 35 | 2.9 |
C: Betamethasone | 8 | 20 | 40 | |||||
Kalay 1997 | 5‐13 wk | E: Orthovisc + PT | Number of patients rating treatment effective/very effective | 19 | 20 | 95 | 35 | 2.9 |
C: PT | 12 | 20 | 60 | |||||
Guler 1996 | 5‐13 wk | E: Orthovisc | Number of patients rating treatment effective/very effective | 11 | 15 | 73 | 40 | 2.5 |
C: Saline | 5 | 15 | 33 |